BACKGROUND: Up to 90% of small cell lung cancer (SCLC) patients suffer cognitive dysfunction. Since donepezil and vitamin E have been somewhat successful in treating other dementias, this study tested the hypothesis that these agents can prevent cognitive decline in SCLC patients. Because accrual was poor, this trial also offered opportunities for suggesting other study designs for future clinical trials on cognitive dysfunction in this group of patients. METHODS: This double blind, placebo controlled trial tested oral donepezil 5 mg/day (with dose escalation to 10 mg after 1 month) and oral vitamin E 1,000 IU/day in SCLC patients after completion of all cancer therapy, including prophylactic cranial irradiation (PCI). Cognition, adverse events, and quality of life were assessed throughout the study period. RESULTS: Only nine of 104 patients enrolled over 15 months (fourdonepezil and vitamin E-treated versus five placebo-exposed), and thus no definitive conclusions could be drawn. Nonetheless, the only patient who manifested a precipitous decline in cognition was taking donepezil and vitamin E. There was also a slight trend of increased gastrointestinal side effects among donepezil and vitamin E-treated patients. There were no notable differences in cognitive stability, adverse events, or quality of life between treatment arms. CONCLUSION: These preliminary findings do not provide enthusiasm for testing donepezil and vitamin E in the manner undertaken here for preventing cognitive dysfunction in SCLC patients. Eligibility criteria and timing of trial intervention are discussed as potential impediments to successful trial completion.
RCT Entities:
BACKGROUND: Up to 90% of small cell lung cancer (SCLC) patients suffer cognitive dysfunction. Since donepezil and vitamin E have been somewhat successful in treating other dementias, this study tested the hypothesis that these agents can prevent cognitive decline in SCLCpatients. Because accrual was poor, this trial also offered opportunities for suggesting other study designs for future clinical trials on cognitive dysfunction in this group of patients. METHODS: This double blind, placebo controlled trial tested oral donepezil 5 mg/day (with dose escalation to 10 mg after 1 month) and oral vitamin E 1,000 IU/day in SCLCpatients after completion of all cancer therapy, including prophylactic cranial irradiation (PCI). Cognition, adverse events, and quality of life were assessed throughout the study period. RESULTS: Only nine of 104 patients enrolled over 15 months (four donepezil and vitamin E-treated versus five placebo-exposed), and thus no definitive conclusions could be drawn. Nonetheless, the only patient who manifested a precipitous decline in cognition was taking donepezil and vitamin E. There was also a slight trend of increased gastrointestinal side effects among donepezil and vitamin E-treated patients. There were no notable differences in cognitive stability, adverse events, or quality of life between treatment arms. CONCLUSION: These preliminary findings do not provide enthusiasm for testing donepezil and vitamin E in the manner undertaken here for preventing cognitive dysfunction in SCLCpatients. Eligibility criteria and timing of trial intervention are discussed as potential impediments to successful trial completion.
Authors: T A Ahles; P M Silberfarb; J Herndon; L H Maurer; A B Kornblith; J Aisner; M C Perry; W L Eaton; L L Zacharski; M R Green; J C Holland Journal: J Clin Oncol Date: 1998-05 Impact factor: 44.544
Authors: J Mahoney; T J Drinka; R Abler; G Gunter-Hunt; C Matthews; S Gravenstein; M Carnes Journal: J Am Geriatr Soc Date: 1994-09 Impact factor: 5.562
Authors: S Frytak; J N Shaw; B P O'Neill; R E Lee; R T Eagan; E G Shaw; R L Richardson; D T Coles; J R Jett Journal: Am J Clin Oncol Date: 1989-02 Impact factor: 2.339
Authors: M Sano; C Ernesto; R G Thomas; M R Klauber; K Schafer; M Grundman; P Woodbury; J Growdon; C W Cotman; E Pfeiffer; L S Schneider; L J Thal Journal: N Engl J Med Date: 1997-04-24 Impact factor: 91.245
Authors: R Komaki; C A Meyers; D M Shin; A S Garden; K Byrne; J A Nickens; J D Cox Journal: Int J Radiat Oncol Biol Phys Date: 1995-08-30 Impact factor: 7.038
Authors: Julia Day; Karolis Zienius; Karin Gehring; David Grosshans; Martin Taphoorn; Robin Grant; Jing Li; Paul D Brown Journal: Cochrane Database Syst Rev Date: 2014-12-18